Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50
KTE-C19-102
Quick answer
Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50 for Relapsed/Refractory Mantle Cell Lymphoma is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Relapsed/Refractory Mantle Cell Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active